Brokerages forecast that Vascular Biogenics Ltd. (NASDAQ:VBLT) will report earnings per share of ($0.10) for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Vascular Biogenics’ earnings, with estimates ranging from ($0.11) to ($0.10). Vascular Biogenics posted earnings of ($0.12) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 16.7%. The business is scheduled to announce its next earnings results on Monday, November 15th.
On average, analysts expect that Vascular Biogenics will report full year earnings of ($0.44) per share for the current fiscal year, with EPS estimates ranging from ($0.45) to ($0.43). For the next fiscal year, analysts forecast that the business will post earnings of ($0.40) per share, with EPS estimates ranging from ($0.43) to ($0.37). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Vascular Biogenics.
Vascular Biogenics (NASDAQ:VBLT) last issued its quarterly earnings results on Sunday, August 15th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). The company had revenue of $0.19 million during the quarter, compared to analyst estimates of $0.37 million. Vascular Biogenics had a negative return on equity of 69.23% and a negative net margin of 3,546.69%.
Shares of NASDAQ:VBLT traded up $0.02 during trading on Wednesday, reaching $2.23. The company had a trading volume of 196,174 shares, compared to its average volume of 645,567. The firm’s fifty day moving average is $2.18 and its 200 day moving average is $2.19. The firm has a market capitalization of $139.08 million, a PE ratio of -4.37 and a beta of 1.00. Vascular Biogenics has a twelve month low of $1.01 and a twelve month high of $3.17.
A number of hedge funds have recently added to or reduced their stakes in VBLT. Goldman Sachs Group Inc. lifted its stake in Vascular Biogenics by 44.1% during the second quarter. Goldman Sachs Group Inc. now owns 16,556 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 5,069 shares during the last quarter. HBK Sorce Advisory LLC acquired a new stake in Vascular Biogenics during the first quarter valued at approximately $44,000. Vident Investment Advisory LLC lifted its stake in Vascular Biogenics by 50.0% during the first quarter. Vident Investment Advisory LLC now owns 22,950 shares of the biopharmaceutical company’s stock valued at $46,000 after purchasing an additional 7,650 shares during the last quarter. Steel Peak Wealth Management LLC acquired a new stake in Vascular Biogenics during the first quarter valued at approximately $48,000. Finally, PVG Asset Management Corp purchased a new stake in shares of Vascular Biogenics in the 1st quarter valued at approximately $53,000. 7.87% of the stock is owned by institutional investors and hedge funds.
About Vascular Biogenics
Vascular Biogenics Ltd. is in the clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of first-in-class treatments for cancer. Its programs include cancer, inflammation, and VB-600 which are focused on treating tumors, ovarian cancer, and chronic immune-related indications.
Featured Article: What is the operating income formula?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.